Biotech investor D.A. Wallach: AI won't cure cancer overnight — China's rising pharma dominance is the bigger story

D.A. Wallach: AI won't cure cancer overnight — China's rising pharma dominance is the bigger story

D.A. Wallach, co-founder and general partner of Time BioVentures, runs both a private biotech fund and a hedge fund. His career path is unusual: he signed to Interscope Records as a college student after a bidding war between Kanye West and Pharrell, became an early Spotify investor through a connection to Mark Zuckerberg's circle, and later backed SpaceX in 2013 before pivoting his focus to life sciences.

The AI hype gap

Wallach's core argument is that AI will improve drug development incrementally, not transform it overnight. The bottleneck in pharma has never been ideas — it's translation. Getting a promising molecule through preclinical work, clinical trials, and FDA approval still requires years of human testing that no model can currently simulate away.

The practical near-term gains are real but mundane: faster FDA filings, better manufacturing quality assurance, reduced administrative drag. If AI shaves a year off a twelve-year development cycle, that's worth tens of millions of dollars for a drug generating $3 billion annually. Valuable, but not the revolution being sold.

When Demis Hassabis says Isomorphic Labs will cure all diseases within ten years, Wallach says scientists with two PhDs and forty years of experience hear it as false hope — and, more charitably, as a legitimacy play by a fund manager with a long time horizon.

“China has both invested tremendously in early stage development and preclinical biotech outsourced labor — all of that work at a quarter of the price. Big pharma companies are now buying double digit percentages of their new drugs from China. The AI labs are prospective buyers of biological data sets, but the pharmas are a little bit guarded about their data.”

China is the bigger structural story

The more consequential shift, in Wallach's view, is China's ascent in pharmaceutical R&D. Over the past five to ten years, Chinese firms have built out early-stage drug discovery and preclinical testing capacity at roughly a quarter of the cost of equivalent U.S. work — and big pharma multinationals have been quietly routing work there for years. Quality has tracked the price advantage upward, partly because many of the scientists doing the work earned their PhDs in the United States before being pushed out.

The result: big pharma is now sourcing double-digit percentages of its new drug pipeline from China. Wallach says this is already material and already reshaping the industry — a structural shift that hasn't gotten the attention the AI narrative has.

The software-for-bio opportunity

Wallach is skeptical that software tools for biotech labs represent a large commercial opportunity in the near term. IT spend in life sciences is low relative to revenues, and the research software stack is dominated by open-source tools — Jupyter notebooks, pipeline libraries written inside university labs. There's a cultural resistance to proprietary SaaS in a community oriented around publishing and sharing. The comparison to Cursor-for-code doesn't quite hold, partly because there's no equivalent open-source foundation to fork.

Manufacturing process improvement is the exception — computer vision over production lines for quality assurance is already generating yield gains at big pharma. But replacing the work of research scientists is a different problem.

FDA regulation

Wallach defends the FDA's dual mandate — proving both safety and efficacy — against the libertarian critique that efficacy should be left to consumers. His framing is blunt: peptides from compounding pharmacies are, in many cases, snake oil, and the complexity of pharmaceutical science is exactly why paternalistic oversight exists. He draws the parallel to the SEC: the conceit of both institutions is that the subject matter is too complicated and the downside of fraud too severe to leave entirely to market forces.

Takeaway: Wallach's bet on biotech is a long-cycle conviction play, not a momentum trade. The AI upside in pharma is real but incremental and rate-sensitive. The structural threat most investors are underweighting is China, which has already captured a double-digit share of big pharma's new drug pipeline through cheaper, high-quality preclinical work — and is not slowing down.